Andy Wardle is part of the biotech investment team in Venrock’s New York office. Prior to Venrock, Andy earned an MBA from Stanford Graduate School of Business and was involved in the formation of Mirum Pharmaceuticals, a biotech focused on childhood rare diseases.
Prior to business school, Andy spent two years at Boston Consulting Group (BCG) London as well as two years as a Physician focused on pediatrics. Andy has published several research articles in peer-reviewed journals. He received his medical degree and bachelor’s from the University of Bristol, graduating with First Class Honors.